Prospects for the prevention and control of pseudomonal infection in children with cystic fibrosis

Paediatric Drugs

Volumn 2, Issue 6, 2000, Pages 451-463

  Høiby, Niels ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; AZLOCILLIN; AZTREONAM; BUDESONIDE; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; IBUPROFEN; IMIPENEM; MEROPENEM; PIPERACILLIN; PIROXICAM; PROBENECID; TOBRAMYCIN;

ANTIBIOTIC THERAPY; ANTIBODY RESPONSE; ANTIINFLAMMATORY ACTIVITY; BACTERIAL COLONIZATION; BIOFILM; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CYSTIC FIBROSIS; DOSE RESPONSE; HEARING LOSS; HUMAN; IMMUNIZATION; INFECTION RISK; KIDNEY DISEASE; LUNG FUNCTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; NEUTROPHIL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PSEUDOMONAS; RECURRENT DISEASE; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBIOTIC PROPHYLAXIS; CHILD; COST-BENEFIT ANALYSIS; CYSTIC FIBROSIS; DRUG COSTS; HUMANS; PHENOTYPE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 0033653318     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200002060-00004     Document Type: Review

References (137)

1. The genetics of cystic fibrosis lung disease
2. Immune response in cystic fibrosis - Helpful or harmful?
3. Cystic fibrosis
4. Lower airway inflammation in infants and young children with cystic fibrosis
5. Gene therapy for cystic fibrosis: A clinical perspective
6. Improved survival in the Danish cystic fibrosis centre results of aggressive treatment
7. Does centralized treatment of cystic fibrosis increase the risk of Pseudomonas aeruginosa infection?
8. Pseudomonas aeruginosa infection in cystic fibrosis. Diagnostic and prognostic significance of Pseudomonas aeruginosa precipitins determined by means of crossed immunoelectrophoresis: A survey
9. Bacteraemia and fungaemia in adults with cystic fibrosis
10. Defective acidification of the biosynthetic pathway in cystic fibrosis
11. Genotypic analysis of respiratory mucous sulphation defects in cystic fibrosis
12. Human beta defensin-1 is a salt-sensitive antibiotic in lung that is activated in cystic fibrosis
13. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung
14. Early pulmonary inflammation in infants with cystic fibrosis
15. Respiratory infections in cystic fibrosis cause by virus, chlamydia and mycoplasma: Possible synergism with Pseudomonas aeruginosa
16. Pharmacologic modulation of salt and water in the airway epithelium in cystic fibrosis
17. Cystic fibrosis
18. A double-blind, placebo controlled, dose ranging study to evaluate the safety and biological efficacy of the lipid-DNA complex GR213487B in the nasal epithelium of adult patients with cystic fibrosis
19. Clinical studies of rhDNase in moderately and severely affected patients with cystic fibrosis - An overview
20. DNase 1 acutely increases cystic fibrosis sputum elastase activity and its potential to induce lung haemorrhage in mice
21. Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening
22. Microbiology of lung infections in cystic fibrosis patients
23. Predictive value of oropharyngeal cultures for identifying lower airway bacteria in cystic fibrosis patients
24. Bronchoalveolar lavage or oropharyngeal cultures to identify lower respiratory pathogens in infants with cystic fibrosis
25. Diagnostic accuracy of oropharyngeal cultures in infants and young children with cystic fibrosis
26. Microbiology of cystic fibrosis
27. Epidemiological investigations of the respiratory tract bacteriology in patients with cystic fibrosis
28. Cystic fibrosis
29. Bacterial flora of respiratory tract in patients wit fibrosis, 1950-1971
30. The microbiology and therapy of cystic fibrosis lung infections
31. Microbiology of airway disease in patients with cystic fibrosis
32. The changing epidemiology of cystic fibrosis
33. Pseudomonas aeruginosa and Burkholderia cepacia infection in cystic fibrosis patients treated in Toronto and Copenhagen
34. Ecology and epidemiology of Pseudomonas aeruginosa
35. Genotyping of Pseudomonas aeruginosa sputum and stool isolates from cystic fibrosis patients - Evidence for intestinal colonization and spreading into toilets
36. Pseudomonas-aeruginosa colonization of the gastrointestinal tract in patients with cystic fibrosis
37. Fecal isolation of Pseudomonas aeruginosa from patients with cystic fibrosis
38. Epidemiology of Pseudomonas aeruginosa infection and the role of contamination of the environment in a cystic fibrosis clinic
39. Microbiology of lung infection in cystic fibrosis
40. Estimated risk of cross-infection with Pseudomonas aeruginosa in Danish Cystic Fibrosis patients
41. Polyagglutinable Pseudomonas aeruginosa from cystic fibrosis patients: A survey
42. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre
43. Pseudomonas aeruginosa cross-colonization and persistence in patients with cystic fibrosis. Use of a DNA probe
44. Nosocomial acquisition of Pseudonionas aeruginosa by cystic fibrosis patients
45. Pseudomonas aeruginosa epidemiology: Major environmental reservoirs, routes of transmission and strategies for prevention
46. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic
47. Acquisition of Pseudomonas aeruginosa in children with cystic fibrosis
48. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995)
49. Epidemiology of Pseudomonas aeruginosa in cystic fibrosis and the possible role of contamination by dental equipment
50. Lung infection with alginate-producing, mucoid Pseudomonas aeruginosa in cystic fibrosis
51. Prognostic implications of initial oropharangeal bacterial flora in patients with cystic fibrosis diagnosed before the age of two years
52. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection
53. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period
54. Mucinophilic and chemotactic properties of Pseudomonas aeruginosa in relation to pulmonary colonization in cystic fibrosis
55. Airway mucins and their role in defence against micro-organisms
56. Role of alginate in the adherence of Pseudomonas aeruginosa
57. Pseudomonas aeruginosa adhesins for tracheobronchial mucin
58. Seasonal onset of initial colonisation and chronic infection with Pseudonionas-aeruginosa in patients with cystic fibrosis in Denmark
59. Pseudomonas aeruginosa exoenzyme-S is an adhesin
60. Role of flagella in pathogenesis of Pseudomonas aeruginosa pulmonary infection
61. Mechanisms involved in the evasion of the host defence by pseudomonas-aeruginosa
62. Host inflammatory responses to first isolation of Pseudomonas aeruginosa from sputum in cystic fibrosis
63. Mucoid conversion of Pseudomonas aeruginosa by hydrogen peroxide: A mechanism for virulence activation in the cystic fibrosis lung
64. Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis
65. Excretion of urinary collagen metabolites correlates to severity of pulmonary disease in cystic fibrosis
66. Pseudomonas acruginosa infection in cystic fibrosis and its management
67. Neutrophil elastase cleaves C3Bi on opsonized pseudomonas as well as CrI on neutrophils to create a functionally important opsonin receptor mismatch
68. Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis
69. The imbalance between granulocyte neutral proteases and antiproteases in bronchial secretions from patients with cystic fibrosis
70. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor
71. Pseudomonas aeruginosa strains possess specific adhesins for laminin
72. Airway adherence of Pseudemonas-aeruginosa - Mucoexopolysaccharide binding to human and bovine airway proteins
73. Interactions of Pseudomonas aeruginosa proteases with the cells of the immune system
74. Detection of proteases of Pseudomonas aeruginosa in immune complexes isolated from sputum of cystic fibrosis patients
75. Influence of growth rate on susceptibility to antimicrobial agents - Modification of the cell envelope and batch and continuous culture studies
76. Induction of beta-lactamase production in Pseudomonas-aeruginosa biofilm
77. Human polymorphonuclear leukocyte response to Pseudomonas aeruginosa grown in biofilm
78. Susceptibility of biofilm cells of Pseudomonas-aeruginosa to bactericidal actions of whole blood and serum
79. Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis
80. Cytokines in sputum and serum from patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs
81. Current understanding of the inflammatory process in cystic fibrosis: Onset and etiology
82. Immunoglobulins and albumin in sputum from patients with cystic fibrosis. A study of protein stability and presence of proteases
83. The role of immune complexes in the pathogenesis of bacterial infections
84. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation
85. Potential of preventing Pseudomonas aeruginosa lung infections in cystic fibrosis patients: Experimental studies in animals
86. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis
87. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis
88. Effect of high-dose ibuprofen in patients with cystic fibrosis
89. A preliminary study on the effect of antiinflammatory treatment in cystic fibrosis patients with Pseudomonas aeruginosa lung infection
90. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Pseudomonas aeruginosa infection
91. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis
92. Prevention of chronic Pseudomonas-aeruginosa colonisation in cystic fibrosis by early treatment
93. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period
94. Cystic fibrosis: Infection
95. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis
96. Early treatment of Pseudomonas-aeruginosa colonization in cystic fibrosis
97. Placebo-controlled, double-blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis
98. Patterns of medical practice in cystic fibrosis: Part II. Use of therapies
99. Efficacy of aerosolized tobramycin in patients with cystic fibrosis
100. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
101. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone
102. Combined imipenem/cilistatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis
103. Human neutrophil elastase and elastase/alpha 1-antiprotease complex in cystic fibrosis - Comparison with interstitial lung disease and evaluation of the effect of intravenously administered antibiotic therapy
104. Plasma tumour necrosis factor-alpha in cystic fibrosis
105. Quality of well-being before and after antibiotic treatment of pulmonary exacerbation in patients with cystic fibrosis
106. Comparison of a beta-lactam alone versus beta-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis
107. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis
108. Maintenance treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis
109. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs
110. Local humoral immunity and immune reactions in the lungs of patients with cystic fibrosis
111. A longitudinal study of immune complex activity and inflammatory response in sputum sol-phase of CF patients: Influence of local steroid treatment
112. Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients
113. Regular 3 monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa
114. Diffuse panbronchiolitis and cystic fibrosis: East meets West
115. Long-term azithromycin may improve lung function in children with cystic fibrosis
116. Tobramycin in patients with cystic fibrosis: Adjustment in dosing interval for effective treatment
117. Serum bactericidal test as a prognostic indicator in acute pulmonary exacerbations of cystic fibrosis
118. Antimicrobial chemotherapy in cystic fibrosis patients
119. Probenecid pharmacokinetics in cystic fibrosis
120. Efficacy of oral fluoroquinolones versus conventional intravenous antipseudomonal chemotherapy in treatment of cystic fibrosis
121. Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF center
122. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis
123. Rapid emergence of resistance in pseudomonas-aeruginosa in cystic fibrosis patients due to in vivo selection of stable partially depressed beta-lactamase producing strains
124. High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment
125. A cost description of an adult cystic fibrosis unit and cost analyses of different categories of patients
126. Drug allergy in cystic fibrosis
127. Retrospective clinical study of hypersensitivity reactions to aztreonam and six other beta-lactam antibiotics in cystic fibrosis patients receiving multiple treatment courses
128. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis
129. Loss of spiral ganglion cells as primary manifestation of aminoglycoside ototoxicity
130. Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis-three year results
131. Clinical evaluation of an octavalent Pseudomonas-aeruginosa conjugate vaccine in plasma donors and in bone marrow transplant and cystic fibrosis patients
132. Safety and immunogenicity of Pseudomonas aeruginosa conjugate-A vaccine in cystic fibrosis
133. Vaccine potential of Pseudomonas aeruginosa mucoid exopolysaccharide (alginate)
134. Experimental immunization with Pseudomonas aeruginosa alginate induces IgA and IgG antibody responses
135. Local IgA and IgG response to intratracheal immunization with Pseudomonas-aeruginosa antigens
136. Antibody production in CF and possibilities for immunotherapy